Clinical Trial Update: Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating loncastuximab tesirine and rituximab followed by DA-EPOCH-R for high-risk diffuse large B-cell lymphoma. Recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• High-grade B-cell Lymphoma with Myc and Bcl2 and or Bcl6 Rearrangements

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Doxorubicin (doxorubicin)
• Etoposide (Etoposide)
• PREDNISONE (Prednisone)
• Rituxan (rituximab)
• Vincristine (vincristine)
• Zynlonta (loncastuximab tesirine)

Snippet

Sponsor: Joseph Tuscano | Conditions: Double-Expressor Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements | Phase 2 | Status: RECRUITING